scispace - formally typeset
J

Jingrong Jean Cui

Researcher at Pfizer

Publications -  26
Citations -  1977

Jingrong Jean Cui is an academic researcher from Pfizer. The author has contributed to research in topics: Protein kinase A & Anaplastic lymphoma kinase. The author has an hindex of 14, co-authored 26 publications receiving 1897 citations. Previous affiliations of Jingrong Jean Cui include Polytechnic University of Bari.

Papers
More filters
Journal ArticleDOI

An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

TL;DR: The antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms, and the therapeutic potential of targeting c-Met with selective small-molecule inhibitors for the treatment of human cancers is shown.
Journal Article

A Selective Small Molecule Inhibitor of c-Met Kinase Inhibits c-Met-Dependent Phenotypes in Vitro and Exhibits Cytoreductive Antitumor Activity in Vivo

TL;DR: The feasibility of selectively targeting c-Met with ATP-competitive small-molecules with high selectivity is demonstrated and the therapeutic potential of targetingc-Met in human cancers is suggested.
Patent

Aminoheteroaryl compounds as protein kinase inhibitors

TL;DR: Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided in this article, where they have activity as protein kinase inhibitors, including as inhibitors of c-MET.
Patent

Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors

TL;DR: In this paper, an anti-met inhibitor of the c-Met protein kinase is described, which is useful in the treatment of abnormal cell growth disorders, such as cancers.
Journal ArticleDOI

Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor

TL;DR: Results show the use of highly selective inhibition of c-Met and provide insight toward targeting tumors exhibiting different mechanisms ofc-Met dysregulation, and also show potent antiangiogenic properties in vitro and in vivo.